血清硬骨素水平及其与 2 型糖尿病患者亚临床动脉粥样硬化的关系。

Serum sclerostin level and its relation to subclinical atherosclerosis in subjects with type 2 diabetes.

机构信息

Department of Internal Medicine (Unit of Diabetes and Metabolism), Faculty of Medicine, Alexandria University, Alexandria, Egypt.

出版信息

J Diabetes Complications. 2019 Aug;33(8):592-597. doi: 10.1016/j.jdiacomp.2019.04.012. Epub 2019 Apr 27.

DOI:10.1016/j.jdiacomp.2019.04.012

PMID:31129005

Abstract

BACKGROUND

Sclerostin, a Wnt-signalling inhibitor, is an established negative regulator of bone formation. However, data regarding its potential importance in vascular disease are less clear. Common carotid artery media thickness (CIMT) assessment and plaque identification using ultrasound imaging are well-recognized tools for identifying and monitoring atherosclerosis. The aim of the present study is to examine the relationship between serum sclerostin and subclinical atherosclerosis (as evidenced by CIMT).

METHODS

This cross-sectional study included 50 subjects with T2DM and 20 subjects as a control group. Multivariable linear regression models were used to assess the association of sclerostin with subclinical atherosclerosis.

RESULTS

Serum sclerostin levels in T2DM patients were significantly higher compared to the control group (167.16 ± 63.60 versus 85.98 ± 23.74 pg/ml, P < 0.0001). A concentration of ≥162.5 pg/ml showed a sensitivity of 90% and a specificity of 86.67% to detect an increased risk of subclinical atherosclerosis. Univariate analysis revealed a significant positive correlation between serum sclerostin and CIMT (r = 0.635, P < 0.001). Sclerostin concentrations remained independently associated with CIMT (β = 63.188 [6.919-119.456], P = 0.017) after adjusting for age and gender.

CONCLUSION

Our data suggest a positive correlation between serum sclerostin level and subclinical atherosclerosis in subjects with type 2 diabetes mellitus.

摘要

背景

骨硬化蛋白（Sclerostin）是一种 Wnt 信号抑制剂，是骨形成的负调控因子。然而，其在血管疾病中潜在重要性的数据尚不清楚。颈动脉中层厚度（CIMT）评估和斑块识别的超声成像，是识别和监测动脉粥样硬化的公认工具。本研究旨在探讨血清骨硬化蛋白与亚临床动脉粥样硬化（通过 CIMT 证实）之间的关系。

方法

本横断面研究纳入 50 例 2 型糖尿病（T2DM）患者和 20 例对照组。采用多变量线性回归模型评估骨硬化蛋白与亚临床动脉粥样硬化的相关性。

结果

T2DM 患者的血清骨硬化蛋白水平明显高于对照组（167.16±63.60 比 85.98±23.74 pg/ml，P<0.0001）。浓度≥162.5 pg/ml 检测亚临床动脉粥样硬化风险增加的灵敏度为 90%，特异性为 86.67%。单变量分析显示，血清骨硬化蛋白与 CIMT 呈显著正相关（r=0.635，P<0.001）。在校正年龄和性别后，骨硬化蛋白浓度仍与 CIMT 独立相关（β=63.188[6.919-119.456]，P=0.017）。